/C O R R E C T I O N from Source -- Oncothyreon Inc./

In TO951 sent today at 08:00 ET please note there is an error in the headline which should instead read "Oncothyreon to Present at JMP Securities Research Conference" and not "Oncothyreon to Present at JMP Securities Healthcare Conference". Corrected copy follows:

Oncothyreon to Present at JMP Securities Research Conference

SEATTLE, WA, May 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 10th Annual JMP Securities Research Conference in San Francisco on Monday, May 9, 2011, at 11:30 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentations will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

------

Oncothyreon to Present at JMP Securities Healthcare Conference

SEATTLE, WA, May 3 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 10th Annual JMP Securities Research Conference in San Francisco on Monday, May 9, 2011, at 11:30 a.m. Pacific Time.

A live and archived webcast of Dr. Kirkman's presentations will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.